PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT
Authors
Vansteenkiste, JNaidoo, J
Faivre-Finn, Corinne
Ozguroglu, M
Villegas, A
Daniel, D
Murakami, S
Hui, R
Lee, K
Cho, BC
Kubota, K
Poole, L
Wadsworth, C
Dennis, P
Antonia, S
Affiliation
University Hospitals Ku Leuven, Leuven/BEIssue Date
2018
Metadata
Show full item recordCitation
Vansteenkiste J, Naidoo J, Faivre-Finn C, Özgüro?lu M, Villegas A, Daniel D, et al. MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT. J Thorac Oncol. 2018 Oct;13(10):S370-371.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.350Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.350Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.350